Xencor Inc Stock Today
| XNCR Stock | USD 12.76 0.11 0.85% |
PerformanceVery Weak
| Odds Of DistressLow
|
Xencor is selling at 12.76 as of the 17th of March 2025; that is 0.85 percent decrease since the beginning of the trading day. The stock's lowest day price was 12.69. Xencor has less than a 16 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 17th of December 2024 and ending today, the 17th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 3rd of December 2013 | Category Healthcare | Classification Health Care |
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California. The company has 70.46 M outstanding shares of which 5.38 M shares are at this time shorted by private and institutional investors with about 11.22 trading days to cover. More on Xencor Inc
Moving together with Xencor Stock
| 0.86 | ENVB | Enveric Biosciences Earnings Call This Week | PairCorr |
Moving against Xencor Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Xencor Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO | Bassil Dahiyat | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP Small-Cap 600, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, NASDAQ Composite Total, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsXencor can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Xencor's financial leverage. It provides some insight into what part of Xencor's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Xencor Inc (XNCR) is traded on NASDAQ Exchange in USA. It is located in 465 North Halstead Street, Pasadena, CA, United States, 91107 and employs 250 people. Xencor is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 899.09 M. Xencor Inc conducts business under Biotechnology sector and is part of Health Care industry. The entity has 70.46 M outstanding shares of which 5.38 M shares are at this time shorted by private and institutional investors with about 11.22 trading days to cover.
Xencor Inc currently holds about 511.92 M in cash with (202.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.57.
Check Xencor Probability Of Bankruptcy
Ownership AllocationThe majority of Xencor outstanding shares are owned by institutional investors. These institutions are usually referred to as non-private investors looking to purchase positions in Xencor Inc to benefit from reduced commissions. Consequently, other corporate entities are subject to a different set of regulations than regular investors in Xencor Inc. Please pay attention to any change in the institutional holdings of Xencor Inc as this could imply that something significant has changed or is about to change at the company.
Check Xencor Ownership Details
Xencor Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Dimensional Fund Advisors, Inc. | 2024-12-31 | 1.5 M | |
| Loomis, Sayles & Company Lp | 2024-12-31 | 1.1 M | |
| Ubs Group Ag | 2024-12-31 | 892.3 K | |
| Woodline Partners Lp | 2024-12-31 | 845.9 K | |
| Nuveen Asset Management, Llc | 2024-12-31 | 837.1 K | |
| Johnson & Johnson | 2024-12-31 | 748.1 K | |
| Northern Trust Corp | 2024-12-31 | 747.2 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 744.6 K | |
| Baker Bros Advisors Lp | 2024-12-31 | 670.4 K | |
| Blackrock Inc | 2024-12-31 | 12.2 M | |
| Primecap Management Company | 2024-12-31 | 9 M |
Xencor Historical Income Statement
Xencor Stock Against Markets
Xencor Corporate Management
| John Desjarlais | Chief Scientific Officer and Sr. VP of Research | Profile | |
| Nancy MD | Executive Officer | Profile | |
| Dane CFA | Senior Strategy | Profile | |
| Jennifer Sandoz | Senior Resources | Profile | |
| Kirk RAC | Senior Assurance | Profile |
Already Invested in Xencor Inc?
The danger of trading Xencor Inc is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Xencor is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Xencor. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Xencor Inc is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Xencor Stock Analysis
When running Xencor's price analysis, check to measure Xencor's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xencor is operating at the current time. Most of Xencor's value examination focuses on studying past and present price action to predict the probability of Xencor's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xencor's price. Additionally, you may evaluate how the addition of Xencor to your portfolios can decrease your overall portfolio volatility.